Autus Asset Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 5.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,865 shares of the company’s stock after selling 1,146 shares during the period. Autus Asset Management LLC’s holdings in Johnson & Johnson were worth $3,045,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of JNJ. WoodTrust Financial Corp boosted its stake in Johnson & Johnson by 3.5% during the 2nd quarter. WoodTrust Financial Corp now owns 44,487 shares of the company’s stock valued at $6,196,000 after purchasing an additional 1,520 shares during the period. Raymond James Trust N.A. lifted its position in shares of Johnson & Johnson by 3.6% in the 2nd quarter. Raymond James Trust N.A. now owns 161,872 shares of the company’s stock worth $22,546,000 after acquiring an additional 5,561 shares during the period. Legacy Advisors LLC lifted its position in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Legacy Advisors LLC now owns 23,639 shares of the company’s stock worth $3,292,000 after acquiring an additional 119 shares during the period. Centre Asset Management LLC lifted its position in shares of Johnson & Johnson by 7.5% in the 2nd quarter. Centre Asset Management LLC now owns 54,200 shares of the company’s stock worth $7,549,000 after acquiring an additional 3,760 shares during the period. Finally, Canton Hathaway LLC lifted its position in shares of Johnson & Johnson by 8.0% in the 2nd quarter. Canton Hathaway LLC now owns 9,741 shares of the company’s stock worth $1,357,000 after acquiring an additional 724 shares during the period. 67.35% of the stock is currently owned by institutional investors.
JNJ stock opened at $130.54 on Friday. The firm has a market cap of $348.11 billion, a PE ratio of 15.96, a P/E/G ratio of 2.23 and a beta of 0.69. The business’s 50-day moving average price is $134.10 and its two-hundred day moving average price is $136.70. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
A number of equities analysts have recently issued reports on the company. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, July 18th. Goldman Sachs Group started coverage on Johnson & Johnson in a report on Tuesday, May 28th. They set a “buy” rating for the company. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a report on Thursday, July 18th. Finally, Bank of America reissued a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $148.56.
In other news, Director Marillyn A. Hewson acquired 3,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.23% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.